Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%.
The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient's prognosis. Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis. Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable.
Written by:
Safriadi F. Are you the author?
Department of Urology, Faculty of Medicine, Padjajaran University - Hasan Sadikin Hospital. Jl. Pasteur no 38 Bandung, Indonesia.
Reference: Acta Med Indones. 2013 Jan;45(1):76-80.
PubMed Abstract
PMID: 23585414
UroToday.com Prostate Cancer Section
